In 2024, the Food and Drug Administration (FDA) significantly invested in reorganizing its internal infrastructure and enhancing operations. These efforts aimed to address the complexities of a global supply chain, rapid innovation in product development and artificial intelligence (AI), and a strong focus on the safety and labeling of FDA-regulated products.
Please see full publication below for more information.
